-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Familial hypercholesterolemia (FH) and lipoprotein (a) (Lp(a)) elevations are genetic disorders associated with premature atherosclerosis cardiovascular disease (ASCVD).
aortic valve stenosis (AVS) is the most common valve heart disease, and low-density lipoprotein cholesterol (LDL-C) and Lp(a) may be involved in their pathophysiological mechanisms.
, researchers looked at the frequency and predictor of severe AVS in patients with FH who need aortic valve replacement (AVR), according to a recent study published in Eur Heart J, an authoritative journal in the field of cardiovascular medicine.
SAFEHEART study is a long-term prospective cohort study of FH populations and uninfed relatives (NAR).
researchers analyzed the frequency and predictive factors of AVR needed in the queue due to AVS.
the study, 5,222 subjects were selected (3,712 FH; NAR 1,310).
50 FH patients (1.48%) and 3 NAR patients (0.27%) needed AVR (ratio of 5.71; 95% confidence interval (CI): 1.78-18.4;
AVR was significantly higher in patients with FH (log-rank=5.93; P=0.015).
Cox regression analysis shows an association between FH and AVR (risk ratio: 3.89; 95% CI: 1.20-12.23; P=0.024), older, past ASCVD, hypertension, LDL-C elevation, and independent predictors of Lp(a) elevation events.
result, there has been a significant increase in AVR demand for AVS in FH patients, especially those who are older and have previously suffered from ASCVD, high blood pressure, elevated LDL-C, and elevated Lp(a).
LDL-C and Lp(a) and the control of hypertension may delay AVS progression in FH patients, but this needs to be tested in clinical trials.